Related Experiment Video
Updated: Apr 10, 2026

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
Abstract:
Treatment of chronic hepatitis C is currently being revolutionised, with the introduction of directly acting antivirals (DAA), including protease, NS5A and polymerase inhibitors. These can be combined in interferon-free oral therapies with unprecedented efficacy and good tolerance. Here, we review the current therapy of chronic hepatitis C, with a particular focus on DAA that are approved in Switzerland today.
Related Concept Videos
Hepatitis
Retrovirus Life Cycles
Cystic Fibrosis: Management
Sinus disease and chronic...
Inhibitors of Viral Protein Synthesis
Drug Therapy
Antianxiety Medications
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

